ANDA 213199, held by Quagen. Fosaprepitant Dimeglumine.
As of Nov 15, 2026, ANDA 213199 (Fosaprepitant Dimeglumine), held by Quagen, was first approved by FDA on Oct 4, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 4, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fosaprepitant DimeglumineEQ 150MG BASE/VIAL ยท powder;intravenous | Fosaprepitant Dimeglumine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
